OLB Group (NASDAQ:OLB) reported quarterly sales of $8.79 million which beat the analyst consensus estimate of $8.52 million by 3.12 percent. This is a 294.70 percent increase over sales of $2.23 million the same period last year.
AbbVie Unveils New Durable Risankizumab Data In Psoriatic Arthritis
AbbVie Inc (NYSE:ABBV) announced new Phase 3 data analyses of KEEPsAKE-1 and KEEPsAKE-2, evaluating Skyrizi (risankizumab) in adults with active psoriatic…